From the Departments of Diagnostic Imaging (J.H.H., R.A.K.),
From the Departments of Diagnostic Imaging (J.H.H., R.A.K.).
AJNR Am J Neuroradiol. 2020 May;41(5):911-916. doi: 10.3174/ajnr.A6509. Epub 2020 Apr 9.
The clinical benefit of pre-hematopoietic cell transplantation sinus CT screening remains uncertain, while the risks of CT radiation and anesthesia are increasingly evident. We sought to re-assess the impact of screening sinus CT on pretransplantation patient management and prediction of posttransplantation invasive fungal rhinosinusitis.
Pretransplantation noncontrast screening sinus CTs for 100 consecutive patients (mean age, 11.9 ± 5.5 years) were graded for mucosal thickening (Lund-Mackay score) and for signs of noninvasive or invasive fungal rhinosinusitis (sinus calcification, hyperattenuation, bone destruction, extrasinus inflammation, and nasal mucosal ulceration). Posttransplantation sinus CTs performed for sinus-related symptoms were similarly graded. Associations of Lund-Mackay scores, clinical assessments, changes in pretransplantation clinical management (additional antibiotic or fungal therapy, sinonasal surgery, delayed transplantation), and subsequent development of sinus-related symptoms or invasive fungal rhinosinusitis were tested (exact Wilcoxon rank sums, Fisher exact test, significance < .05).
Mean pretransplantation screening Lund-Mackay scores ( = 100) were greater in patients with clinical symptoms (8.07 ± 6.00 versus 2.48 ± 3.51, < .001) but were not associated with pretransplantation management changes and did not predict posttransplantation sinus symptoms ( = 21, = .47) or invasive fungal rhinosinusitis symptoms ( = 2, = .59).
Pre-hematopoietic cell transplantation sinus CT does not meaningfully contribute to pretransplantation patient management or prediction of posttransplantation sinus disease, including invasive fungal rhinosinusitis, in children. The risks associated with CT radiation and possible anesthesia are not warranted in this setting.
造血前细胞移植前鼻窦 CT 筛查的临床获益仍不确定,而 CT 辐射和麻醉的风险日益明显。我们试图重新评估筛查鼻窦 CT 对移植前患者管理和预测移植后侵袭性真菌性鼻鼻窦炎的影响。
对 100 例连续患者(平均年龄 11.9 ± 5.5 岁)进行移植前非对比性筛查鼻窦 CT,评估黏膜增厚(Lund-Mackay 评分)和非侵袭性或侵袭性真菌性鼻鼻窦炎的征象(鼻窦钙化、高信号、骨破坏、窦外炎症和鼻黏膜溃疡)。对因鼻窦相关症状而进行的移植后鼻窦 CT 进行类似评分。对 Lund-Mackay 评分、临床评估、移植前临床管理变化(附加抗生素或真菌治疗、鼻-鼻窦手术、延迟移植)以及随后出现的鼻窦相关症状或侵袭性真菌性鼻鼻窦炎的相关性进行了检验(精确 Wilcoxon 秩和检验、Fisher 确切检验,显著性<.05)。
有临床症状的患者(8.07 ± 6.00 与 2.48 ± 3.51,<.001)的平均移植前筛查 Lund-Mackay 评分较高,但与移植前管理变化无关,也不能预测移植后鼻窦症状( = 21,= .47)或侵袭性真菌性鼻鼻窦炎症状( = 2,= .59)。
造血前细胞移植前鼻窦 CT 对移植前患者管理或预测儿童移植后鼻窦疾病(包括侵袭性真菌性鼻鼻窦炎)无明显意义。在这种情况下,CT 辐射和可能的麻醉相关风险是不合理的。